
|Articles|October 1, 2003
- Pharmaceutical Executive-10-01-2003
Table of Contents
Table of Contents
Advertisement
Articles in this issue
about 22 years ago
Balanced Scorecard for R&Dover 22 years ago
Pharma's Value Propositionover 22 years ago
Sharing IP, Sharing RiskNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
3
JP Morgan 2026: Biogen’s New Company Emerges
4
Communicating Credibility and Timelines to Public-Market Investors at the 2026 J.P. Morgan Healthcare Conference
5




